Survey methodology and respondent profiles
The results in this report are from the Cyber Security Hub survey which we fielded to subscribers from May and June 2020 to benchmark actual results from H1 2020 vs. expectations for H2 2020. A…
Source: www.cshub.com and Read More
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
